Global Anal Fistula Treatment Market Size study & Forecast, by Treatment Type (Surgical and Non-Surgical), by Application (Intersphincteric Fistula, Transsphincteric Fistula, Suprasphincteric Fistula, Others), by End-User (Hospitals, Ambulatory Surgical C

Global Anal Fistula Treatment Market Size study & Forecast, by Treatment Type (Surgical and Non-Surgical), by Application (Intersphincteric Fistula, Transsphincteric Fistula, Suprasphincteric Fistula, Others), by End-User (Hospitals, Ambulatory Surgical Centers, Others), and Regional Analysis, 2022-2029

Global Anal Fistula Treatment Market is valued at approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than 3.8% over the forecast period 2022-2029. Anal fistula is a condition in which a tiny, tunnel-like structure forms between the anus and the point where the gut terminates. They arise when an infection spreads nearby to the area where an abscess is developing. After the abscess is removed, a condition develops where a little tunnel forms. Surgery is typically advised as a therapy for this, since the condition may be so uncomfortable, causing bowel incontinence, pain, fever, and other symptoms including irritation and aches and pains. The market growth is driven by key factors such as high incidence rate of anal fistula and recurrence rate and rising cases of Inflammatory Bowel Diseases (IBD) Such As Crohn's Disease and Ulcerative Colitis.

The market for anal fistula treatment is predicted to expand quickly because of the rise in inflammatory bowel disorders including Crohn's disease and ulcerative colitis, the introduction of new products, and the increased popularity of non-surgical treatments like fibrin glue injection and adipose-derived stem cell therapy. For instance, study conducted in 2022 by researchers at the University of Nottingham with funding from Crohn's & Colitis UK and Coeliac UK revealed that Crohn's and Colitis are far more common than initially assumed in the population of the United Kingdom (UK). According to the same survey, 1 in every 123 individuals in the UK suffers from ulcerative colitis or Crohn's disease. In the UK, this leads to a total of roughly 500,000 persons who have inflammatory bowel disease (IBD). Inflammatory bowel disease so affects a large number of people in the UK even though it is not very common. However, high cost associated with the procedure stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Anal Fistula Treatment Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is registered as the largest revenue generating region owing to the high public and private healthcare spending as well as the significant number of patients with inflammatory bowel illnesses. However, Asia Pacific is expected to be the fastest growing region due to initiatives to improve healthcare infrastructure and increase in healthcare expenditure.

Major market players included in this report are:
Karl Storz Se & Co. Kg
Cook Medical
Novo Surgical Inc.
Integra LifeSciences
Avante Health Solutions
Advin Health Care
Medtronic plc
Signum Surgical
Angiplast Pvt. Ltd.
Biolitec AG


Recent Developments in the Market:
 In March 2022, The FDA approved Ossium Health, Inc.'s application for OSSM-001, a mesenchymal stem cell (MSC) product, to be considered as an investigational new drug (IND) for the treatment of refractory perianal fistulas in Crohn's disease patients.
 In February 2022, Takeda published the first INSPIRE six-month interim analysis data, showing that 65% of patients in both cohorts who were assessed at six months had achieved clinical remission. The INSPIRE trial (EUPAS24267) is an observational, multicenter, post-approval, open-enrollment study conducted in Europe to assess the safety and efficacy of Alofisel (darvadstrocel) in patients with complicated perianal fistulas and Crohn's disease (CD).


Global Anal Fistula Treatment Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Treatment type, Application, End-user, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*


The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.
The detailed segments and sub-segment of the market are explained below:

By Treatment Type:
Surgical
Non-Surgical

By Application:
Intersphincteric Fistula
Transsphincteric Fistula
Suprasphincteric Fistula
Others

By End-User:
Hospitals
Ambulatory Surgical Centers
Others

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World

Companies Mentioned

Karl Storz Se & Co. Kg
Cook Medical
Novo Surgical Inc.
Integra LifeSciences
Avante Health Solutions
Advin Health Care
Medtronic plc
Signum Surgical
Angiplast Pvt. Ltd.
Biolitec AG

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.